A B S T R A C T This study was designed to ascertain whether renal vascular angiotensin receptors differ from other systemic angiotensin receptors and whether, on that basis, antagonists with greater specificity for the renal vasculatuLre can be defined. Femoral and renal blood flow and their responses to angiotensin II (All) and its heptapeptide analogue, 1-des Asp All (AIII), were measured with an electromagnetic flowmeter in 26 dogs. For the kidney, the threshold doses of All and AIII were identical (2.5+0.27 vs. 2.3+0.35 pmol/100 ml renal blood flow, with similar doseresponse curves. In contrast, All had a greater pressor effect (P < 0.001) and produced more femoral vasoconstriction (P < 0.001) than AIII. All four antagonists studied (1-Sar, 8-Ala All [P113]; 8-Ala All; 1-des Asp, 8-Ala AII; 1-des Asp, 8-Ile All) induced parallel shifts in the renal blood flow response to AII and AIII. P113 induced greater blockade than 8-Ala All (P < 0.001) which, in turn, was more effective than 1-des Asp, 8-Ala AII (P < 0.001). 1-des Asp, 8-Ile AII was as effective as P 113. Each analogue induced an identical inhibition of the renal vascular response to All and AIII. In addition, All and AIII induced cross-tachyphylaxis. All lines of evidence stuggest that AII and AIII act on a single receptor in the kidney, which differs at least functionally from other systemic vascular receptors.
The possibility that heptapeptide analogues represent angiotensin antagonists with greater specificity for the renal vasculature was pursued in a model in which the renin-angiotensin system is activated. Acute, partial thoracic inferior vena caval occlusion was induced in an additional 16 dogs. P113 induced progressive, doserelated hypotension and a limited increase in renal blood flow in this model. The 1-des Asp, 8-Ile AII analogue, conversely, induced a consistent, larger, doserelated renal blood flow increase, with significantly INTRODUCTION Several observations have stuggested that the renal vascular receptor for angiotensin II (All)' differs from systemic vascular angiotensin receptors. First, the renal vasculature is especially sensitive to All (1) . Second, the 1-Sar, 8 -Ala All analogue (P113) induces a dose-related reduction in renal blood flow which parallels the response to All, but exerts only a limited pressor effect (2, 3) . Third, the observation that 1-des Asp All (AIII) constricts the renal vasculature as effectively as All (4), despite a limited pressor activity, suggests that this agent does not influence other vascular beds in parallel.
Pharmacologic interruption of the renin-angiotensin system in animals (5-7) and man (8, 9) 8 -Ala All, 30-3,000 ng/kg per min; 1-des Asp, 8-Ile All, 3-100 ng/kg per min. Recovery of response to angiotensin was assured before proceeding with another antagonist when different antagonists were used in the same dog.
Tachyphylaxis to AII (three studies) or AIII (two studies) was induced with a continuous 5-10-,ug/min infusion of either agent into the renal artery. This dose resulted in an acute, approximately 75%, reduction in renal blood flow which gradually returned to within 30% of control over the next 5-10 min when it stabilized. Responses to bolus doses of both All and AIII (10 ng/kg) and norepinephrine (10 ,ug); (Levophed, Winthrop Laboratories, New York) were assessed before initiating the continuous angiotensin infusion and repeated after blood flow stabilized during the continued angiotensin infusion.
Responses to angiotensin antagonists in the caval dog. The relative effects on renal blood flow and blood pressure of interrupting the renin-angiotensin system with the octapeptide, P113, and the heptapeptide, 1-des Asp, 8-Ile All, were evaluated in a model in which the renin-angiotensin system is activated and in which P113 causes hypotension; acute, partial thoracic inferior vena caval occlusion (11) . Briefly, in 16 anesthetized dogs, a balloon-tipped catheter was placed in the thoracic vena cava under fluoroscope guidance. After a control period, the balloon was inflated to increase lower abdominal caval pressure by 7.5-10 mm Hg and caval pressure was maintained at this level by adjusting a micrometer syringe on the catheter. P113 (10 dogs) or 1-des Asp, 8 Ile All (6 dogs) was then infused intravenously in log-dose increments over the range of 30-3,000 ng/kg per min. Each animal received at least three doses and each dose was maintained for at least 5 min. Arterial and caval pressure and renal blood flow were monitored continuously in each animal.
Means have been presented with the standard error of the mean as the index ofdispersion. Tests ofstatistical significance were carried out with the t test, analysis of variance or for regression, where applicable. In some cases, indicated in the text, the results were assessed with a nonparametric technique, the Fisher Exact Test (FET). The null hypothesis was rejected when a P value of less than 0.05 was obtained (12) .
RESULTS

Chlaracterization of the renal vascular angiotentsin
receptor. The responses of arterial blood pressure, femoral and renal blood flows to All and AIII infused intranveously are summarized in Fig. 1 . All was considerably more active as a pressor agent over the entire dose range (P < 0.001; FET). For example, 100 ng/kg per min of AIII induced a pressor response of 15.7+2.1 mm Hg. The All dose required to induce this change in blood pressure xvas approximately 20 ng/kg per min. The difference in the response of the femoral vascular bed to All and AIII was even larger (P = 0.001; FET). AIII at 100 ng/kg per min reduced femoral blood flow 18.1±5.9 ml/min. The All dose required to induce this response was approximately 10 ng/kg per min. Conversely, the renal vaseular bed responded similarly to the two agents; a statistically significant difference could not be demonstrated (P > 0.2; FET).
The similarity in the response of the renal vascular Renal Angiotensin Antagonists 529 (Fig. 3) . After a marke(d initial reduictioni in rencal blood flow in eachi case, flow retllrne(l progressively towards the control level wifthin minulttes, generally stabilizing at a somiiewlhat reduced level within 5-10 miin. Responsiveness to norepinel)phrinie wvas well suistained (Fig. 3) . However Fig. 7 were typical.
In the dog shown in Fig. 7 ., a P113 dose of 300 nglkg per min was associated with a small, but unequivocal increase in renal blood flow despite the fall in arterial pressure. Increasing dose was associated with a continuing decrement in arterial pressure and with the largest dose used, 3,000 ng/kg per min, a reversal in the direction of the renal blood flow response occurred. A similar pattern was evident in each dog receiving P113, but the dose which increased renal blood flow differed in each dog. As a result, no P113 dose induced an increase in average renal blood flow for all dogs and flow was reduced significantly (P < 0.05) at a P113 dose of 3 Ag/kg per min (Fig. 8) .
The dose-related hypotension which occurred with P113 was significant at 100 ng/kg per min (P < 0.01; Fig. 8 ).
In contrast, infusion of the heptapeptide analogue after partial caval occlusion was associated with a better-sustained arterial blood pressure (Figs. 7 and 8 ) and a dose-related, well-sustained blood flow increase. The blood flow increase (Fig. 8 ) became significant at a dose of 300 ng/kg per min (P < 0.01) and increased with increasing dose. In individual animals, increasing the heptapeptide dose did result in an arterial blood pressure fall, which limited the blood flow response, as is evident in Fig. 7 .
For the group as a whole, a significant increase in renal blood flow was not identified at any P113 dose (Fig. 8) , because the optimal dose varied in different dogs. A flow increase which occurred in one dog at a given dose was offset by a greater tendency for blood pressure and flow to fall at that dose in another dog. When the maximum flow increase induced by P113 was assessed, an average increase of 0.25 ±0.19 ml/min per g was found. Despite an identical capacity to block renal vascular responses to All, the heptapeptide analog induced significantly less hypotension. Perhaps as a consequence, the renal 
DISCUSSION
Circumnstantial evidence reviewed in the introduction raised the possibility that the renal receptor differs stufficiently from systemic angiotensin receptors such that angiotensin analogues with greater specificity for the kidney could be found. In particular, the observation that All and AIII had a similar influence on the renal vasculature despite the striking differences in their capacity to raise blood pressure (4), provided a clue to the avenue which might lead to antagonists with greater specificity for the kidney. The primary thrust of this study was to compare the systemic and renal responses to All and AIII, to characterize the renal vascular receptor to these angiotensins more specifically and, based on new evidence for an identical renal receptor, to establish the principle that heptapeptide analogs would have greater specificity for the renal than the systemic vasculature.
Three unrelated lines of evidence now suggest an identical renal receptor for All and its 1-des Asp heptapeptide analogue (AIII). (6, 7, 14, 16) , and i-desAsp 8-lie An (ng/kgmin) where it has been tested, the normal renal response to angiotensin is either blunted or reversed (13) (14) (15) . 7 Tracings of the effect of partial thoracic caval The latter observation in particular has been thought mn and angiotensin analogue on blood pressure and to reflect occupation of angiotensin receptors. new approaches to therapy in these syndromes.
Renal Angiotensin Antagonists
Unfortunately, in each of these conditions, administration of the angiotensin antagonist has been associated with hypotension sufficiently consistent and severe as to limit the renal response (6) (7) (8) .
Partial occlusion of the thoracic inferior vena cava in the dog has been widely employed as a model in which there is disordered volume homeostasis, abnormalities of renal perfusion and function, and activation of the renin-angiotensin system (7, 11) . As yet, there is no broad agreement as to the mediator of the renal response. Two groups have employed angiotensin antagonists to assess the renal response in this model, with conflicting results (7, 20) . Freeman et al. (7) reported an increase in renal blood flow with a low dose of P113 (0.2 ,ug/kg per min) infused into the renal artery. Hypotension and a reduction in renal blood flow occurred with higher doses. Slick et al. (20) reported that the same agent in the same dose did not influence renal perfusion, assessed as p-aminohippurate clearance. Several observations in this study help to explain the apparent conflict. The use of graded P113 doses demonstrated an increase in renal blood flow in response to P113 infused intravenously. The flow increase generally occurred with small doses and was dissipated with increasing P113 dose, presumably at least in part because of resultant hypotensioni. In view of our observation that different doses of P113 were optimal in different animals, it is not surprising that a study based on a single dose f;ailed to document the renal response. A contributing factor may also have been the intrinsic activity of P113, which is a partial agonist in the kidney (2, 3, 18) . In general, partial agonists show the greatest blockade at low doses, and their intrinsic activity tends to dominate the response with increasing doses (21) .
The heptapeptide analogue induced an even more striking renal vascular response associated with a better sustained blood pressure level in the caval dog. These results suggest that angiotensin was involved both in sustaining blood pressure and in the renal blood flow reduction in this model. The role played by angiotensin in the abnormalities of renal function in this model, and in others, remains to be defined. An unequivocal demonstration will demand an angiotensin antagonist which induces a maximal renal vascular response in the absence of hypotension, and which is effectively free of intrinsic activity on the kidney at the optimal dose. Certainly heptapeptide analogues defined in this study represent an improvement over P113, but they are by no means ideal. The relative inactivity of the 1-des Asp, 8-Ala analogue precluded its use, since such large doses would be required. Only limited amounts of each analogue were available. The isoleucine heptapeptide analogue, in common with isoleucine octapeptide analogues, was much more effective as an antagonist: unfortunately, as for the isoleucine octapeptide analogues (22, 23) , the agent had considerable intrinsic activity on the renal vasculature.
Observations made in this study also provide insight into the role played by angiotensin III as a determinant of renal vascular responses to angiotensin. In the case of aldosterone release from the adrenal, it has been suggested that AIII represents the hormone and that AII is a prohormone or precursor (24) The major evidence in that system is the greater efficacy of heptapeptide analogues in blocking the adrenal response to All. In this study, the heptapeptide analogues were not more efficacious in blocking the renal vascular response to All. Moreover, the identical blockade of renal vascular responses to All and AIII induced by P113, an analogue resistant to degradation by aminopeptidase, suggests that conversion of AII to AIII is not required for the action of AII on the renal vasculature.
Antagonists have been extremely useful in characterizing receptors for a wide variety of agonists, including the adrenergic, cholinergic, and histamine systems (25) . Earlier investigation has suggested that the angiotensin receptors in myocardium, the central nervous system, the adrenal, and vascular smooth muscle differ rather strikingly (21, (26) (27) (28) (29) . This study has extended those observations to indicate that within the vascular system itself there must be functional heterogeneity among angiotensin receptors. As a result, heptapeptide analogues provide entr6e to greater specificity for the renal vasculature. The potential utility of angiotensin antagonists in reversing the renal response in a number of syndromes including acute renal failure (6) , hepatic cirrhosis (7, 8) , and congesitve heart failure (personal observation) has been limited by the attendant hypotension. It appears that activation of the renin-angiotensin system contributes to the maintenance of blood pressure in these syndromes, as well as others (5, 9) . In view of the accumulating evidence that angiotensin plays a role in the pathogenesis of these processes, this avenue merits further investigation.
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